Charcot Marie Tooth Disease Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 - DelveInsight

DelveInsight's "Charcot Marie Tooth Disease Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Charcot Marie Tooth Disease, historical and forecasted epidemiology as well as the Charcot Marie Tooth Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Charcot Marie Tooth Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Charcot Marie Tooth Disease Market Forecast
https://www.delveinsight.com/sample-request/charcot-marie-tooth-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Charcot Marie Tooth Disease Market Report:
• The Charcot Marie Tooth Disease market size was valued approximately USD 58 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2022-2036).
• In March 2026, NMD Pharma A/S announced that it will present both a poster and a late-breaking oral session featuring safety and efficacy results from its Phase 2a SYNAPSE-CMT study of ignaseclant (formerly NMD670). The study evaluates the therapy in patients with Charcot-Marie-Tooth disease types 1 and 2, and the data will be shared at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 in Orlando, Florida, from March 8-11, 2026.
• In February 2026, Cycle Pharmaceuticals announced that they have completed the acquisition of Applied Therapeutics.
• In February 2026, NMD Pharma announced the topline results from its Phase IIa SYNAPSE-CMT study evaluating ignaseclant in patients living with CMT types 1 or 2. There are currently no FDA-approved therapies for the treatment of CMT disease.
• In March 2025, Actio Biosciences announced first participant dosed in phase I clinical trial of abs-0871, a novel TRPV4 inhibitor, for the treatment of CMT disease 2C.
• In September 2025, Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company focused on developing transformative therapies for rare diseases, announced that it has concluded a meeting with the U.S. Food and Drug Administration (FDA) to discuss a potential New Drug Application (NDA) submission for govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase (SORD) Deficiency (CMT-SORD), targeted for the third quarter of 2025.
• In June 2025, Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the first patient has been dosed in its first-in-human clinical trial evaluating VCA-894A, an antisense oligonucleotide (ASO) therapy, for a rare IGHMBP2 gene variant causing Charcot-Marie-Tooth disease Type 2S (CMT2S). The patient, diagnosed at age five, has this rare inherited neuromuscular disorder, which progressively causes muscle weakness and loss of motor function. CMT2S affects fewer than 1 in 1,000,000 people globally, with its severity and symptoms varying based on the diverse genetic variants linked to CMT disease.
• In May 2025, Applied Therapeutics' rare disease candidate faced another setback after failing a late-stage clinical trial, compounding the challenges of a drug previously rejected by the FDA five months ago. The drug, govorestat, a selective aldose reductase inhibitor, was tested in the Phase 2/3 Inspire study involving 56 patients with sorbitol dehydrogenase deficiency (SORD), a form of Charcot-Marie-Tooth (CMT) disease. The trial did not meet its primary endpoint of improving performance in the 10-meter walk-run test (10MWRT) at 12 months versus placebo. The company noted that 10MWRT has since been removed from the CMT Functional Outcome Measure, partially contextualizing the outcome.
• In May 2025, Augustine Therapeutics NV ("Augustine"), a biotechnology company developing novel therapies for neuromuscular, neurodegenerative, and cardio-metabolic diseases by inhibiting the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, announced that the first patient has been dosed in its Phase I clinical trial of lead candidate AGT-100216, the first peripherally restricted, selective HDAC6 inhibitor.
• In March 2025, ENCell, a prominent biopharmaceutical firm specializing in cell and gene therapy CDMO and innovative drug development, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational therapy EN001 for the treatment of Charcot-Marie-Tooth disease (CMT).
• In March 2025, Augustine Therapeutics NV ("Augustine"), a biotech company specializing in innovative treatments for neuromuscular, neurodegenerative, and cardio-metabolic disorders through HDAC6 enzyme inhibition, has announced the successful completion of its Series A funding round. The company raised EUR 77.7 million (USD 84.8 million) in total. This oversubscribed round was co-led by Novo Holdings and Jeito Capital, with continued support from existing investors including Asabys Partners who previously led a EUR 17.5 million closing in 2024 alongside Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the CMT Research Foundation (U.S.), and Newton Biocapital.
• In January 2025, The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to NMD670, an investigational oral treatment for Charcot-Marie-Tooth disease (CMT). This designation is reserved for therapies aimed at preventing, diagnosing, or treating rare conditions that impact fewer than 200,000 individuals in the U.S. It supports the advancement of rare disease treatments by offering benefits like clinical trial tax credits, fee exemptions, and seven years of market exclusivity upon potential approval.
• The disease shows high genetic diversity, with over 100 genes linked to various Charcot-Marie-Tooth (CMT) subtypes. Among the most frequently involved genes are PMP22, MPZ, GJB1, and MFN2. Notably, CMT1A-resulting from duplication of the PMP22 gene-represents around 60-70% of all CMT cases.
• According to the secondary analysis, the estimated Charcot-Marie-Tooth Disease Prevalence disease ranges from approximately 9-28 per 100,000 population worldwide.
• According to the Charcot Marie Tooth Association, CMT disease affects more than 3 million people globally.
• CMT disease is the most common inherited neuropathy, with an estimated prevalence ranging from 1 in 1,500 to 1 in 10,000 individuals in France.
• As per secondary analysis, CMT1A accounts for approximately 60-70% of all CMT disease cases and is caused by a duplication on chromosome 17p11.2, resulting in overexpression of the Peripheral Myelin Protein 22 (PMP22) gene.
• CMT disease is generally considered a rare disease; however, epidemiological surveys conducted in Europe and the United States have reported a prevalence of approximately 1 per 2,500 people, while in Japan, it is around 1 per 10,000 people.
• CMT disease affects an estimated 1 in 2,500 people in the United States. Although CMT disease is classified as a rare disease (affecting fewer than 200,000 people in the US), experts believe the actual number of affected individuals may be significantly higher. Globally, an estimated 2.6 million people are affected by CMT disease.
• Emerging Charcot-Marie-Tooth disease pipeline candidates, including siRNA therapies, antisense oligonucleotides, HDAC6 inhibitors, and ClC-1 inhibitors, are expected to broaden future treatment options and increase competition within the CMT therapeutic landscape over the forecast period.
• Key Charcot Marie Tooth Disease Companies: Pharnext, DTx Pharma, Augustine therapeutics, Addex Therapeutics, InFlectis BioScience, Chong Kun Dang pharmaceutical, ENCell, HELIXMITH, Pharnext SA, MedDay Pharmaceuticals, and others
• Key Charcot Marie Tooth Disease Therapies: PXT3003, DTx-1252, HDAC6i, Research programme: GABAB PAM, IFB-088, CKD-510, EN001, Engensis, PXT3003, MD1003, and others
• The Charcot Marie Tooth Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Charcot Marie Tooth Disease pipeline products will significantly revolutionize the Charcot Marie Tooth Disease market dynamics.

Charcot Marie Tooth Disease Overview
Charcot-Marie-Tooth (CMT) disease is a group of inherited neurological disorders that affect the peripheral nerves, which connect the brain and spinal cord to the muscles and sensory organs. This progressive condition damages the myelin sheath (protective covering of nerves) or the nerve fibers themselves, leading to weakness, muscle wasting, and reduced sensation in the legs, feet, and sometimes the hands. Symptoms typically appear in adolescence or early adulthood and may include difficulty walking, foot deformities, and a loss of fine motor skills. While there is no cure for CMT, physical therapy, occupational therapy, and orthopedic devices can help manage symptoms and improve quality of life.

Get a Free sample for the Charcot Marie Tooth Disease Market Report:
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Charcot Marie Tooth Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Charcot Marie Tooth Disease Epidemiology Segmentation:
The Charcot Marie Tooth Disease market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Prevalent Cases of Charcot Marie Tooth Disease in the 7MM
• Diagnosed Prevalent Cases of Charcot Marie Tooth Disease in the 7MM
• Gender-specific Diagnosed Prevalent Cases of Charco Marie Tooth Disease in the 7MM
• Age-specific Diagnosed Prevalent Cases of Charcot Marie Tooth Disease in the 7MM
• Type-specific Diagnosed Prevalent Cases of Charco Marie Tooth Disease in the 7MM

Download the report to understand which factors are driving Charcot Marie Tooth Disease epidemiology trends @ Charcot Marie Tooth Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/charcot-marie-tooth-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Charcot Marie Tooth Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Charcot Marie Tooth Disease market or expected to get launched during the study period. The analysis covers Charcot Marie Tooth Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Charcot Marie Tooth Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Charcot Marie Tooth Disease Therapies and Key Companies
• Govorestat: Applied Therapeutics
• Ignaseclant (NMDP-08): NMD Pharma
• ABS-0871: Actio biosciences
• AGT-100216: Augustine Therapeutics
• VCA-894A: Vanda Pharmaceuticals
• PXT3003: Pharnext
• DTx-1252: DTx Pharma
• HDAC6i: Augustine therapeutics
• Research programme: GABAB PAM: Addex Therapeutics
• IFB-088: InFlectis BioScience
• CKD-510: Chong Kun Dang pharmaceutical
• EN001: ENCell
• Engensis: HELIXMITH
• PXT3003: Pharnext SA
• MD1003: MedDay Pharmaceuticals

Discover more about therapies set to grab major Charcot Marie Tooth Disease market share @ Charcot Marie Tooth Disease Treatment Landscape
https://www.delveinsight.com/sample-request/charcot-marie-tooth-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Charcot Marie Tooth Disease Market Strengths
• The increasingly prevalent population worldwide is likely to cause a surge in treatment options, and consequently, the market will witness a boost in upcoming years.
• The shortfall of approved therapies might provide goodspace for emerging therapies in the market.

Charcot Marie Tooth Disease Market Opportunities
• The unavailability of approved treatment options offers a great opportunity for the investment and development of novel therapies.
• Medications with better safety and effectiveness, which provide an optimum cure, are the current unmet need of theCMT disease market

Scope of the Charcot Marie Tooth Disease Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Charcot Marie Tooth Disease Companies: Pharnext, DTx Pharma, Augustine therapeutics, Addex Therapeutics, InFlectis BioScience, Chong Kun Dang pharmaceutical, ENCell, HELIXMITH, Pharnext SA, MedDay Pharmaceuticals, and others
• Key Charcot Marie Tooth Disease Therapies: PXT3003, DTx-1252, HDAC6i, Research programme: GABAB PAM, IFB-088, CKD-510, EN001, Engensis, PXT3003, MD1003, and others
• Charcot Marie Tooth Disease Therapeutic Assessment: Charcot Marie Tooth Disease current marketed and Charcot Marie Tooth Disease emerging therapies
• Charcot Marie Tooth Disease Market Dynamics: Charcot Marie Tooth Disease market drivers and Charcot Marie Tooth Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Charcot Marie Tooth Disease Unmet Needs, KOL's views, Analyst's views, Charcot Marie Tooth Disease Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.